Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

JPMorgan raised the firm’s price target on Apellis (APLS) to $37 from $35 and keeps an Overweight rating on the shares. The firm updated the ...

Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals' Empaveli (pegcetacoplan) as the first treatment ...

A new study finds cuts in copay assistance for retina injections are harming lower-income communities and leading to poorer ...

LONG BEACH, Calif. -- Depletion of a payment assistance program has translated into worse vision outcomes for older patients ...

A total of 7 analyst ratings have been received for Ultragenyx Pharmaceutical, with the consensus rating being Outperform. The average one-year price target stands at $61.14, suggesting a potential ...

L ONG BEACH, Calif. -- Methotrexate, during and after surgery for primary retinal detachment, has produced "amazing" early ...

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

The FDA approved multiple groundbreaking treatments in July, enhancing options across patient populations. The FDA maintained its momentum in July, issuing a wave of drug approvals across diverse ...

There are key steps to take that can ensure equitable access to pegcetacoplan, explained Carla Nester, MD, MSA, FASN, who also highlighted remaining questions on long-term outcomes, safety, and ...